louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05910853: Whole Blood Biospecimen Collection for Subjects With Fanconi Anemia
Official title: Whole Blood Biospecimen Collection for Subjects With Fanconi Anemia
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Fanconi Anemia
Lead sponsor: Sanguine Biosciences
Sponsor class: INDUSTRY
First posted: 2023-06-20
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants have been diagnosed with Fanconi Anemia

Brief summary: The primary study objective is to collect biospecimen samples (e.g., blood) from participants diagnosed with Fanconi Anemia. The biospecimens will be used to create a biorepository that can be used to identify disease associated biomarkers and potential targets with immune and multi-omics profiling. The disease sample collection and analysis will be the foundation for an extensive network of biospecimen access and linked datasets for future translational research.


Eligibility criteria: Inclusion Criteria:

* The participant is willing and able to provide written informed consent
* The participant is willing and able to provide appropriate photo identification
* Participants aged 18 to 85
* Participants have been diagnosed with Fanconi Anemia complementation group A

Exclusion Criteria:

* Participants who are pregnant or are nursing
* Participants with a known history of HIV, hepatitis, or other infectious diseases Participants who have taken an investigational product in the last 30 days Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months

Primary outcomes:
measure: Biospecimen Samples collect from patients with Fanconi Anemia participants diagnosed with Fanconi Anemia.
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Woburn
country: United States
facility: Sanguine Biosciences
state: Massachusetts
Study officials:
affiliation: Sanguine Biosciences
name: Andrew C Frisina, M.S.
role: STUDY_CHAIR
References:
Clinical trial NCT00721253: Visual Outcomes of Subjects Bilaterally Implanted With ReSTOR Aspheric +4 vs. Tecnis or Acri.LISA
Official title: Visual Outcomes of Subjects Bilaterally Implanted With ReSTOR Aspheric +4 vs. Tecnis Multifocal Intraocular Lens (IOL) or Acri.LISA IOL
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Cataract
Keywords: ReSTOR
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2008-07-24
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a study to compare visual outcomes of subjects bilaterally implanted w/ReSTOR to subjects bilaterally implanted with the Tecnis Multifocal Intraocular Lens (IOL) or Acri.LISA IOL


Eligibility criteria: Inclusion Criteria:

* Diagnosed with cataracts

Exclusion Criteria:

* Preexisting condition likely to confound results; 1 D astigmatism by preoperative K-readings

Primary outcomes:
measure: Uncorrected Visual Acuity (UCVA) at Distance, Near and Intermediate
timeFrame: 6 months
Secondary outcomes:
measure: Contrast Sensitivity
timeFrame: 6 months
measure: Defocus Curve
timeFrame: 6 months post-operative
Other outcomes:
Locations:
city: Fort Worth
country: United States
facility: Contact Alcon Call Center for Trial Locations
state: Texas
Study officials:
References:
Clinical trial NCT00264953: HD11 for Intermediate Stages
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hodgkin´s Lymphoma
Keywords: Hodgkin´s lymphoma
intermediate stages
Lead sponsor: University of Cologne
Sponsor class: OTHER
First posted: 2005-12-13
Enrollment: 1395
Sex: ALL
Minimum age (years): 16
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: This study is designed to (1) compare the efficacy of the BEACOPP regimen with that of ABVD as a 4-cycle chemotherapy combined with an involved field irradiation and (2) to define the optimum radiation dose comparing of 30 to 20 Gy in the same context.


Eligibility criteria: Inclusion Criteria:

* Hodgkin´s lymphoma (histologically proven)
* CS (PS) IA, IB, IIA, with one of the risk factors a-d CS (PS) IIB only with risk factor c or d

  1. bulky mediastinal mass (\> 1/3 maximum transverse thorax diameter)
  2. extranodal involvement
  3. ESR \> 50 (A), \> 30 (B-symptoms)
  4. 3 or more lymph node areas involved
* written informaed consent

Exclusion Criteria:

* Leukocytes \<3000/microl
* Platelets \<100000/microl
* Hodgkin´s Disease as "composite lymphoma"
* Activity index (WHO) \< grade 2

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Cologne
name: Volker Diehl, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Eich HT, Diehl V, Gorgen H, Pabst T, Markova J, Debus J, Ho A, Dorken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Dohner H, Borchmann P, Muller-Hermelink HK, Muller RP, Engert A. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010 Sep 20;28(27):4199-206. doi: 10.1200/JCO.2010.29.8018. Epub 2010 Aug 16.
citation: Hay AE, Klimm B, Chen BE, Goergen H, Shepherd LE, Fuchs M, Gospodarowicz MK, Borchmann P, Connors JM, Markova J, Crump M, Lohri A, Winter JN, Dorken B, Pearcey RG, Diehl V, Horning SJ, Eich HT, Engert A, Meyer RM; Conducted by the NCIC Clinical Trials Group (Canada) and German Hodgkin Study Group (GHSG). An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma. Ann Oncol. 2013 Dec;24(12):3065-9. doi: 10.1093/annonc/mdt389. Epub 2013 Oct 11.
citation: Boll B, Gorgen H, Fuchs M, Pluetschow A, Eich HT, Bargetzi MJ, Weidmann E, Junghanss C, Greil R, Scherpe A, Schmalz O, Eichenauer DA, von Tresckow B, Rothe A, Diehl V, Engert A, Borchmann P. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol. 2013 Apr 20;31(12):1522-9. doi: 10.1200/JCO.2012.45.4181. Epub 2013 Mar 18.
Clinical trial NCT02155153: Role of Chewing Gum in Reducing Post Operative Ileus After Reversal of Ileostomy
Official title: The Effect of Gum Chewing on the Duration of Postoperative Ileus and Total Length of Hospital Stay After Reversal of Ileostomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postoperative Ileus
Lead sponsor: Services Hospital, Lahore
Sponsor class: OTHER_GOV
First posted: 2014-06-04
Enrollment: 100
Sex: ALL
Minimum age (years): 15
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Postoperative ileus is generally referred to as the transient impairment of bowel motility after abdominal or other surgery and diagnosed by postoperative abdominal pain vomiting constipation and distension.

The potential complications of prolonged POI include increased postoperative pain, increased nausea and vomiting, pulmonary complications, poor wound healing, delay in resuming oral intake, delay in postoperative mobilization, prolonged hospitalization, and increased health-care costs. The estimated economic impact of POI in the United States is $7.5 billion per year, excluding the expenses of work loss.

In view of these complications and economic burden a number of pharmacologic and non-pharmacologic strategies have been adopted by the doctors all over the world to reduce the burden of postoperative ileus.These programs involve transverse or curved surgical incisions, removal of nasogastric tubes at the end of anesthesia, intraoperative and postoperative analgesia, early postoperative feeding, mobilization, and gum chewing.

The use of gum chewing has emerged as a new and simple modality for decreasing POI. And reviews have concluded that there is consistent benefit for patients from gum chewing after the intestinal surgery; colonic surgery and gynecological surgery.

This study is based on the hypothesis that postoperative gum chewing is beneficial in prevention of postoperative ileus after reversal of ileostomy.


Eligibility criteria: Inclusion Criteria:

1. Patients of either gender with age ranging from 15 to 60 years.
2. Patients whose ileostomies were made for typhoid or tuberculous perforation
3. Patients with no distal obstruction on loopogram.

Exclusion Criteria:

- 1. Patients with age less than 15 years and greater than 60. 2. Patients having co-morbid factors such as diabetes and ischemic heart disease.

3. Patients whose ileostomy was made for any condition other than typhoid or tuberculosis.

Primary outcomes:
measure: passage of flatus
timeFrame: within 48 hours after the operation
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Services hospital lahore
state: Punjab
Study officials:
affiliation: Professor of Surgery
name: Mahmood Ayyaz, FCPS FACS
role: STUDY_DIRECTOR
References:
Clinical trial NCT06878053: Benefit of Ethanol Sclerotherapy of Endometriomas Before Ovarian Stimulation on Pregnancy Rates in IVF/ICSI
Official title: Benefit of Ethanol Sclerotherapy of Endometriomas Before Ovarian Stimulation on Pregnancy Rates in IVF/ICSI
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Infertile Women Undergoing IVF or ICSI
Lead sponsor: Poissy-Saint Germain Hospital
Sponsor class: OTHER
First posted: 2025-03-14
Enrollment: 174
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 43
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Evaluation of progressive pregnancy rates (with an embryo with cardiac activity at 12 weeks), on a first attempt at IVF/ICSI (fresh and frozen embryo transfers) following the discovery of one or two endometrioma(s) of 30 to 80 mm, without a history of cystectomy, and comparison between the two groups: ethanol sclerotherapy and therapeutic abstention


Eligibility criteria: Inclusion Criteria:

* Infertile women aged 18 to 43,
* Presenting one or 2 endometriotic cysts of 30 mm to 80 mm long axis, confirmed by ultrasound and/or pelvic MRI and without signs of atypia,
* With indication of IVF/ICSI, first IVF/ICSI after the discovery of endometriosis cyst(s),
* Having given their consent.

Exclusion Criteria:

* A history of ovarian cystectomy,
* A non-homogeneous cyst that cannot be punctured (risk of incomplete aspiration),
* Complex adnexal image that cannot exclude an associated hematosalpinx (communicating hematosalpinx, tissue component),
* A recent tubo-ovarian infection,
* An active, untreated vaginal infection,
* Anticoagulant treatment at a therapeutic dose,
* All adult patients protected by law (under guardianship or curatorship),
* Problems understanding the French language,
* Participation in intervention research,
* All patients not affiliated to the social security system.

Primary outcomes:
measure: cumulative rate of active pregnancies
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02512653: Biological Standarization of Cupressus Arizonica Allergen Extract to Determine the Biological Activity in Histamine Equivalent Units (HEP)
Official title: Biological Standarization of Cupressus Arizonica Allergen Extract to Determine the Biological Activity in Histamine Equivalent Units (HEP)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Allergy to Tree Pollen
Keywords: Allergy to Cupressus pollen
Lead sponsor: Laboratorios Leti, S.L.
Sponsor class: INDUSTRY
First posted: 2015-07-31
Enrollment: 33
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Biological Standardization of Cupressus arizonica Allergen Extract.

Detailed description: This is an open, unblinded and non-randomized biological assay. The study design is a slight modification of the recommendations proposed by the Nordic Guidelines.

Eligibility criteria: Inclusion Criteria:

* Subject has provided written informed consent, appropriately signed and dated by subject.
* Subject can be male or female of any race and ethinic group.
* Age 18 years and 60 years ata the study inclusión day.
* Positive clinical history of inhalatory allergy to Cupressus arizonica.
* A positive prick test with a standarices commercially Cupressus arizonica allergen extract.
* A positive prick test with positive control of histamine 10 mg/ml.
* A positive test for specific IgE to Cupressus arizonica.

Exclusion Criteria:

* Immunotherapy in the past 5 years with an allergen extract Cupressus arizonca or other allergen extract than may interfere with the allergene to be tested.
* Use of drugs that may interfere before and after with the skin reactions.
* Treatment with certain drugs.

Primary outcomes:
measure: Wheal size area (mm2) on the skin at the site of the puncture during the inmediate phase
timeFrame: Test sites should be inspected and recorded 15-20 min after application
Secondary outcomes:
Other outcomes:
Locations:
city: Fuenalabrada
country: Spain
facility: Hospital Universitario de Fuenlabrada
state: Madrid
city: Majadahonda
country: Spain
facility: Hospital Universitario Puerta de Hierro
state: Madrid
Study officials:
affiliation: Laboratorios Leti, S.L.U
name: Lena Erbiti
role: STUDY_CHAIR
References:
Clinical trial NCT02863653: Participation Restrictions in Rheumatoid Arthritis
Official title: Factors Associated With Participation Restrictions in Individuals With Rheumatoid Arthritis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Rheumatoid Arthritis
Keywords: social participation
International Classification of Functioning
Lead sponsor: Federal University of Minas Gerais
Sponsor class: OTHER
First posted: 2016-08-11
Enrollment: 81
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: For this cross-sectional study involved 81 individuals treated between June 2009 and August 2010 in Clinics Hospital, Universidade Federal de Minas Gerais in Belo Horizonte, Brazil. Recruted by convenience sampling

Brief summary: Objective: To evaluate what factors contribute to social participation restrictions in subjects with Rheumatoid Arthritis (RA), considering the model International Classification of Functioning (ICF).

Methods: Cross-sectional study with 81 individuals with Rheumatoid Arthritis, using instruments to measure two constructs of component social participation.

Detailed description: In this study the definition of social participation considered several areas, such as marriage and family, work, leisure, religion, economy, and politics which are based in the social scales of the questionnaires SF-36 and AIMS2.

Eligibility criteria: Inclusion Criteria:

* Age greater than 18 years of age
* Mental capacity as assessed by the Brazilian version of Mini Mental State Examination
* Diagnosis of RA according to the American College of Rheumatology (ACR) 1987 criteria established by attending service rheumatologist.

Exclusion Criteria:

* Individuals who had undergone surgery of the upper limbs, were unable to comply with the protocol for data collection, or with non-corrected visual deficits that could interfere with their functionality were excluded

Primary outcomes:
measure: The Short Form Instruments (social aspect) and Arthritis Impact Measurement Scale (social interaction) were used as outcome measures to assess the social participation according to the International Classification of Functioning, Disability and Health
timeFrame: June 2009 to August 2010
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01194453: Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer
Official title: A Phase 2,Open-label Study of First Line Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced and Metastatic Non Small Cell Lung Cancer and Biomarker Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Non-small Cell Lung Cancer
Efficacy
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2010-09-03
Enrollment: 288
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A phase III trial has demonstrated that in advanced non-small cell lung cancer (NSCLC) cisplatin/ pemetrexed provides similar efficacy with better tolerability and more convenient administration than cisplatin/gemcitabine. Moreover,this trial showed survival differences based on histologic type. The investigators want to research some biomarkers that can predict clinical outcomes.


Eligibility criteria: Inclusion Criteria:

1. Chemotherapy-naive patients with histologically or cytologically confirmed adenocarcinoma and large-cell carcinoma, classified as stage IIIB not amenable to curative treatment or stage IV
2. With at least one unidimensionally measurable lesion according to the Response Evaluation Criteria in Solid Tumors;
3. with an Eastern CooperativeOncology Group performance status of 0 or 1,
4. At least 18 years of age
5. adequate bone marrow reserve and organ function including calculated creatinine clearance 45 mL/min based on the standard Cockcroft and Gault formula.
6. Prior radiation therapy was permitted if it was completed at least 4 weeks before study treatment
7. patients had fully recovered from its acute effects.

Exclusion Criteria:

1. peripheral neuropathy \> National Cancer Institute Common Toxicity Criteria grade 1
2. progressive brain metastases,
3. uncontrolled third-space fluid retention before study entry.
4. Patients unable to interrupt aspirin and other nonsteroidal anti-inflammatory drugs or if they were unable or unwilling to take folic acid, vitamin B12, or corticosteroids.

Primary outcomes:
measure: Progression Free Survival (PFS)
timeFrame: 36months
Secondary outcomes:
measure: Response Rate
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Cancer Center of Sun Yat-Sen University (CCSU)
state: Guangdong
Study officials:
affiliation: Cancer Center of Sun Yat-Sen University (CCSU)
name: Li Zhang, MD
role: STUDY_CHAIR
References:
citation: Huang Y, Liu Y, Zhou J, Xu N, Li B, Wu G, Fang J, Li K, Liu X, Liu W, Lu Y, Wang M, Liu W, Liang H, Zhang Y, Huang C, Wang S, Wang Y, Yu S, Chang J, Wang Z, Hu Z, Zhang L. [A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi. 2012 Oct;15(10):576-82. doi: 10.3779/j.issn.1009-3419.2012.10.03. Chinese.
Clinical trial NCT02260453: Coronary Angiography Before Elective Carotid Endarterectomy in Patients With Asymptomatic Coronary Artery Disease
Official title: Randomized Controlled Trial Analyzing the Role of Systematic Preoperative Coronary Angiography Before Elective Carotid Endarterectomy in Patients With Asymptomatic Coronary Artery Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Carotid Stenosis
Coronary Stenosis
Lead sponsor: University of Roma La Sapienza
Sponsor class: OTHER
First posted: 2014-10-09
Enrollment: 426
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the potential benefit of systematic preoperative coronary angiography followed by selective coronary artery revascularization on the incidence of myocardial infarction (MI) in patients without a history of coronary artery disease (CAD) and undergoing carotid endarterectomy (CEA).

Detailed description: Patients candidates for CEA, with no history of CAD, a normal electrocardiogram (ECG), and a normal cardiac ultrasound were randomized in two groups. In group A (n = 216) all patients underwent coronary angiography before CEA +- coronary artery revascularization. In group B (n = 210) CEA was performed without coronary angiography.

Eligibility criteria: Inclusion Criteria:

* indication for carotid endarterectomy
* no clinical sign or history of ischemic heart disease
* no electrical signs of cardiac ischemia
* left ventricular ejection fraction \>50% at transthoracic echocardiogram.

Exclusion Criteria:

* disabling stroke (mRS ≥3)
* non atherosclerotic carotid disease
* severe intracranial carotid artery stenosis
* contra-indications to heparin, aspirin or clopidogrel.

Primary outcomes:
measure: Non-fatal and fatal myocardial infarction
timeFrame: 30 days through year 3
Secondary outcomes:
measure: All-cause and cardiovascular mortality
timeFrame: 30 days through year 3
Other outcomes:
Locations:
Study officials:
affiliation: University of Roma La Sapienza
name: Giulio Illuminati, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Illuminati G, Schneider F, Greco C, Mangieri E, Schiariti M, Tanzilli G, Barilla F, Paravati V, Pizzardi G, Calio' F, Miraldi F, Macrina F, Totaro M, Greco E, Mazzesi G, Tritapepe L, Toscano M, Vietri F, Meyer N, Ricco JB. Long-term results of a randomized controlled trial analyzing the role of systematic pre-operative coronary angiography before elective carotid endarterectomy in patients with asymptomatic coronary artery disease. Eur J Vasc Endovasc Surg. 2015 Apr;49(4):366-74. doi: 10.1016/j.ejvs.2014.12.030. Epub 2015 Feb 18.
Clinical trial NCT01393353: Cognitive Training in Parkinson's Disease
Official title: A Computerized, Multidimensional and Disease Specific Training of Cognition in Patients With M. Parkinson
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Mental Competence
Lead sponsor: University Hospital, Basel, Switzerland
Sponsor class: OTHER
First posted: 2011-07-13
Enrollment: 39
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study evaluates a computerized cognitive therapy in patients with Parkinson's disease who have a mild cognitive impairment or mild dementia. The control group is "trained" using Nintendo Wii. The main outcome parameter is a neuropsychological evaluation.


Eligibility criteria: Inclusion Criteria:

* Parkinson's disease and mild cognitive impairment (MCI) or mild dementia

Exclusion Criteria:

* Moderate or severe dementia, other pathologies of the brain, physical conditions that prevent the participation, unsufficient knowledge of german, pregnancy

Primary outcomes:
measure: Neuropsychological parameters: Tests of episodic memory, working memory, executive functions, visio-construction
timeFrame: Neuropsychological assessment immediatly before and after the training and 6 month later
Secondary outcomes:
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: University Hospital Basel
Study officials:
affiliation: University Hospital Basel, Neurology
name: Peter Fuhr, Prof.
role: PRINCIPAL_INVESTIGATOR
References: